» Articles » PMID: 20942954

Relative Replication Capacity of Phenotypic SIV Variants During Primary Infections Differs with Route of Inoculation

Overview
Journal Retrovirology
Publisher Biomed Central
Specialty Microbiology
Date 2010 Oct 15
PMID 20942954
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Previous studies of human and simian immunodeficiency virus (HIV and SIV) have demonstrated that adaptive mutations selected during the course of infection alter viral replicative fitness, persistence, and pathogenicity. What is unclear from those studies is the impact of transmission on the replication and pathogenicity of the founding virus population. Using the SIV-macaque model, we examined whether the route of infection would affect the establishment and replication of two SIVmne variants of distinct in vitro and in vivo biological characteristics. For these studies, we performed dual-virus inoculations of pig-tailed macaques via intrarectal or intravenous routes with SIVmneCl8, a minimally pathogenic virus, and SIVmne027, a highly pathogenic variant that replicates more robustly in CD4+ T cells.

Results: The data demonstrate that SIVmne027 is the dominant virus regardless of the route of infection, indicating that the capacity to replicate efficiently in CD4+ T cells is important for fitness. Interestingly, in comparison to intravenous co-infection, intrarectal inoculation enabled greater relative replication of the less pathogenic virus, SIVmneCl8. Moreover, a higher level of SIVmneCl8 replication during primary infection of the intrarectally inoculated macaques was associated with lower overall plasma viral load and slower decline in CD4+ T cells, even though SIVmne027 eventually became the dominant virus.

Conclusions: These results suggest that the capacity to replicate in CD4+ T cells is a significant determinant of SIV fitness and pathogenicity. Furthermore, the data also suggest that mucosal transmission may support early replication of phenotypically diverse variants, while slowing the rate of CD4+ T cell decline during the initial stages of infection.

Citing Articles

Antiviral potency of long-acting islatravir subdermal implant in SHIV-infected macaques.

Pons-Faudoa F, Di Trani N, Capuani S, Facchi I, Wood A, Nehete B J Control Release. 2023; 366:18-27.

PMID: 38142963 PMC: 10922355. DOI: 10.1016/j.jconrel.2023.12.031.


Clearance of HIV-1 or SIV reservoirs by promotion of apoptosis and inhibition of autophagy: Targeting intracellular molecules in cure-directed strategies.

Chen M, Li M, Budai M, Rice A, Kimata J, Mohan M J Leukoc Biol. 2022; 112(5):1245-1259.

PMID: 35362118 PMC: 9522917. DOI: 10.1002/JLB.4MR0222-606.


Serial Passaging of Human-Simian Immunodeficiency Virus Clones Identifies Characteristics for Persistent Viral Replication.

Thippeshappa R, Polacino P, Chandrasekar S, Truong K, Misra A, Aulicino P Front Microbiol. 2021; 12:779460.

PMID: 34867922 PMC: 8636705. DOI: 10.3389/fmicb.2021.779460.


Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates.

Pons-Faudoa F, Sizovs A, Shelton K, Momin Z, Niles J, Bushman L Adv Ther (Weinh). 2021; 4(3).

PMID: 33997267 PMC: 8114879. DOI: 10.1002/adtp.202000163.


Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant.

Pons-Faudoa F, Di Trani N, Sizovs A, Shelton K, Momin Z, Bushman L Pharmaceutics. 2020; 12(10).

PMID: 33080776 PMC: 7590004. DOI: 10.3390/pharmaceutics12100981.


References
1.
Derdeyn C, Decker J, Bibollet-Ruche F, Mokili J, Muldoon M, Denham S . Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science. 2004; 303(5666):2019-22. DOI: 10.1126/science.1093137. View

2.
Kimata J, Overbaugh J . The cytopathicity of a simian immunodeficiency virus Mne variant is determined by mutations in Gag and Env. J Virol. 1997; 71(10):7629-39. PMC: 192112. DOI: 10.1128/JVI.71.10.7629-7639.1997. View

3.
Learn G, Muthui D, Brodie S, Zhu T, Diem K, Mullins J . Virus population homogenization following acute human immunodeficiency virus type 1 infection. J Virol. 2002; 76(23):11953-9. PMC: 136917. DOI: 10.1128/jvi.76.23.11953-11959.2002. View

4.
Overbaugh J, Rudensey L, Papenhausen M, Benveniste R, Morton W . Variation in simian immunodeficiency virus env is confined to V1 and V4 during progression to simian AIDS. J Virol. 1991; 65(12):7025-31. PMC: 250821. DOI: 10.1128/JVI.65.12.7025-7031.1991. View

5.
Forte S, Harmon M, Pineda M, Overbaugh J . Early- and intermediate-stage variants of simian immunodeficiency virus replicate efficiently in cells lacking CCR5. J Virol. 2003; 77(17):9723-7. PMC: 187416. DOI: 10.1128/jvi.77.17.9723-9727.2003. View